Benedicte Querton

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

Rajeka Lazarus, Benedicte Querton, Irena Corbic Ramljak et al. · The Lancet Infectious Diseases · 2022 · 47 citations · Full text

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults

Rajeka Lazarus, Christian Taucher, Claire Brown et al. · Journal of Infection · 2022 · 23 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +10

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

Christian Taucher, Rajeka Lazarus, Hanna Dellago et al. · Journal of Infection · 2023 · 14 citations · Full text

Vaccination, Vaccine Safety, Interim Analysis +11

Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial

Rajeka Lazarus, Christian Taucher, Claire Brown et al. · 2021 · 11 citations · Full text

Low Dose, Immunodeficiencies, Immunology +23